ZY7

(3E)-3-[(2,4-DIMETHOXYPHENYL)METHYLIDENE]-3,4,5,6-TETRAHYDRO-2,3'-BIPYRIDINE

Find entries where: ZY7

is present as a standalone ligand in 1 entries

Find related ligands:

Chemical Component Summary
Name	(3E)-3-[(2,4-DIMETHOXYPHENYL)METHYLIDENE]-3,4,5,6-TETRAHYDRO-2,3'-BIPYRIDINE
Identifiers	3-[(3E)-3-[(2,4-dimethoxyphenyl)methylidene]-5,6-dihydro-4H-pyridin-2-yl]pyridine
Formula	C₁₉ H₂₀ N₂ O₂
Molecular Weight	308.374
Type	NON-POLYMER
Isomeric SMILES	COc1ccc(c(c1)OC)\C=C\2/CCCN=C2c3cccnc3
InChI	InChI=1S/C19H20N2O2/c1-22-17-8-7-14(18(12-17)23-2)11-15-5-4-10-21-19(15)16-6-3-9-20-13-16/h3,6-9,11-13H,4-5,10H2,1-2H3/b15-11+
InChIKey	RPYWXZCFYPVCNQ-RVDMUPIBSA-N

Chemical Details
Formal Charge	0
Atom Count	43
Chiral Atom Count	0
Bond Count	45
Aromatic Bond Count	12

Drug Info: DrugBank

DrugBank ID	DB05708 ?
Name	GTS-21
Groups	investigational
Description	GTS-21 (also known as DMBX-A), is a novel, small-molecule, orally active and selective alpha-7 nicotinic acetylcholine (nACh) receptor agonist that has demonstrated memory and cognition enhancement activity in human clinical trials. Athenagen licensed the exclusive rights to the compound and a related library of analogs as part of the acquisition of Osprey Pharmaceutical Company in April 2006. GTS-21 has been studied in multiple Phase I studies in healthy volunteers and one Phase I/II study in schizophrenic patients. In all studies, the compound was well tolerated. In a Phase I multi-dose, double-blind, placebo controlled study in healthy adults, GTS-21 also demonstrated cognitive enhancement across all doses, with a statistically significant improvement in attention related and memory related tasks (Kitagawa, et al. Neuropsychopharmacology (2003), 28, 542-551).
Synonyms	3-(2,4-dimethoxybenzylidene)anabaseine DMXB-Anabaseine DMXB-A GTS-21 Dimethoxybenzylidene anabaseine
Indication	Investigated for use/treatment in alzheimer's disease and schizophrenia and schizoaffective disorders.
Categories	Benzene Derivatives Cholinergic Agents Cholinergic Agonists Cytochrome P-450 CYP1A2 Substrates Cytochrome P-450 CYP2E1 Substrates Cytochrome P-450 Substrates Neurotransmitter Agents Nicotinic Agonists
CAS number	148372-04-7

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
Neuronal acetylcholine receptor subunit alpha-7	MRCSPGGVWLALAASLLHVSLQGEFQRKLYKELVKNYNPLERPVANDSQP...	unknown
Cytochrome P450 1A2	MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPL...	unknown	substrate
Cytochrome P450 2E1	MSALGVTVALLVWAAFLLLVSMWRQVHSSWNLPPGPFPLPIIGNLFQLEL...	unknown	substrate

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682